Immune Pharma and EpiCept complete merger

27 August 2013

Israel-based Immune Pharmaceuticals (Nasdaq OMX Stockholm Exchange: IMNP) says it has now completed its previously-announced merger with US firm EpiCept (The Pharma Letter November 8, 2012) which combines Immune’s antibody therapeutic platform focused on the treatment of inflammatory diseases and cancer with EpiCept’s early stage cancer program and its late-stage topical pain product AmiKet (amitriptyline 4%, ketamine 2% cream).

The new company, also called Immune Pharmaceuticals, will be 81% owned by Immune shareholders and 19% by those of EpiCept. The completion of the deal followed the recent one for 40 reverse stock split for EpiCept.

Immune Pharmaceuticals was started three years ago in Israel with a focus on antibody therapeutics. It obtained exclusive worldwide rights to bertilimumab for systemic indications, an antibody developed by Cambridge Antibody Technology that was sitting on a shelf at iCo Therapeutics. It also licensed antibody nanoparticle conjugate technology from Hebrew University and began to develop a promising pipeline of targeted therapies in inflammation and orphan indications.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK